Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 38, 2009, Pages 16375-16380

  Nguyen, Quang Dé ^a   Smith, Graham ^a   Glaser, Matthias ^a   Perumal, Meg ^a   Årstad, Erik ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cell death; Response to treatment; Small animal imaging

Indexed keywords

CASPASE 3; CASPASE 7; ISATIN SULFONAMIDE F18; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CONTROLLED STUDY; DRUG BINDING; ENZYME ACTIVITY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; XERORADIOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUORODEOXYGLUCOSE F18; HUMANS; ISATIN; MALE; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS;

ANIMALIA; MURINAE;

EID: 70349481530     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901310106     Document Type: Article

References (37)

1. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111-121.
2. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
3. Chang J, et al. (2000) Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145-2152.
4. Dubray B, et al. (1998) In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother Oncol 46:185-191. (Pubitemid 28109177)
5. Eisenhauer EA, et al. (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247.
6. Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231-241.
7. Porter AG, Janicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99-104.
8. Chu W, et al. (2005) N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies J Med Chem 48:7637-7647. (Pubitemid 41698804)
9. Lee D, et al. (2000) Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 275:16007-16014. (Pubitemid 30366906)
10. Faust A, et al. (2007) The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)s ulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging 51:67-73. (Pubitemid 46824663)
11. Kopka K, et al. (2006) 5-pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J Med Chem 49:6704-6715. (Pubitemid 44749738)
12. Zhou D, et al. (2009) [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: Synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. Org Biomol Chem 7:1337-1348.
13. Podichetty AK, et al. (2009) Fluorinated isatin derivatives. Part 2: New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis. J Med Chem 52:3484-3495.
14. Podichetty AK, et al. (2009) Fluorinated isatin derivatives. Part 1: Synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl] isatins as potent caspase-3 and -7 inhibitors. Bioorg Med Chem 17:2680-2688.
15. Zhou D, et al. (2006) Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 16:5041-5046. (Pubitemid 44247712)
16. Davis DW, et al. (2003) Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res 9:955-960.
17. Mohsin SK, et al. (2005) Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468.
18. Smith G, et al. (2008) Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem 51:8057-8067.
19. Janicke RU (2008) MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat.
20. Cohen GM (1997) Caspases: The executioners of apoptosis. Biochem J 326:1-16.
21. Galluzzi L, et al. (2008) No death without life: Vital functions of apoptotic effectors. Cell Death Differ 15:1113-1123. (Pubitemid 351850963)
22. Kroemer G, et al. (2009) Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16:3-11. (Pubitemid 41553979)
23. Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P (2008) Apoptosis and necrosis: Detection, discrimination and phagocytosis. Methods 44:205-221. (Pubitemid 351296447)
24. Lee D, et al. (2001) Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem 44:2015-2026. (Pubitemid 32884524)
25. Browder T, et al. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886. (Pubitemid 30207647)
26. Aschoff AP, Gunther E, Jirikowski GF (2000) Tissue transglutaminase in the small intestine of the mouse as a marker for apoptotic cells. Colocalization with DNA fragmentation. Histochem Cell Biol 113:313-317. (Pubitemid 30256974)
27. Schmitz JE, Kettunen MI, Hu DE, Brindle KM (2005) 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn Reson Med 54:43-50. (Pubitemid 40898395)
28. Zhao M, Pipe JG, Bonnett J, Evelhoch JL (1996) Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73:61-64. (Pubitemid 126422064)
29. Krishnan AS, et al. (2008) Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology 246:854-862.
30. Banihashemi B, et al. (2008) Ultrasound imaging of apoptosis in tumor response: novel preclinical monitoring of photodynamic therapy effects. Cancer Res 68:8590-8596.
31. Blankenberg FG, Vanderheyden JL, Strauss HW, Tait JF (2006) Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis. Nat Protoc 1:108-110.
32. Collingridge DR, et al. (2003) In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope Br J Cancer 89:1327-1333.
33. Grimberg H, et al. (2009) Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 14:257-267.
34. Barthel H, et al. (2003) 3-′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791-3798. (Pubitemid 36793068)
35. Kenny L, et al. (2007) Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347. (Pubitemid 47312585)
36. Leyton J, et al. (2005) Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65:4202-4210. (Pubitemid 40775658)
37. Hamano Y, et al. (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64:1570-1574. (Pubitemid 38428672)